Daiichi Sankyo Co., Ltd has agreed to pay €150 million for the German biotechnology company, U3 Pharma AG, which researches fully-human antibodies as potential therapies for cancer. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals
